The size of the Epigenetics Market in the Asia Pacific is estimated to be worth USD 160.00 million in 2022 and USD 336.05 million by 2027, growing at a CAGR of 16% from 2022 to 2027.
The market for Epigenetics in the APAC region is expected to be driven by the proliferation of chronic diseases such as cancer and increasing awareness regarding the need for epigenetics. Also, the increasing applications of epigenetics in non-oncology diseases are expected to fuel market growth. The other factors, such as decreasing sequencing costs, growing geriatric population, and surge in genome mapping programs, are fuelling the market growth. In addition, increasing preference for personalized medicine and target therapies are more likely to influence the market growth.
On the other hand, the Improving technological advancements in the healthcare sector in emerging countries such as China, India, and Japan contribute to the APAC regional market growth. Key market players are adopting advanced epigenetic procedures and strategic developments, which are predicted to fuel market growth. The major players in the region are conducting research and development activities that are expected to provide lucrative growth opportunities for the market players.
Furthermore, increasing investments and funding by the government and non-government organizations for the R&D activities and for the development of healthcare infrastructure are encouraging the Epigenetics market. In addition, the market participants are implementing various strategies such as partnerships between academic, pharmaceutical, and biotechnology companies for epigenetics studies, which are projected to impact market growth positively.
However, the high cost of instruments and lack of skilled professionals are expected to restrain the market growth.
This research report on the APAC Epigenetics Market has been segmented & sub-segmented into the following categories:
By Research Area:
By Instruments & Consumables:
Geographically, the APAC is one of the emerging regional markets and is expected to have significant growth rate in the global epigenetics market. The market growth is majorly attributed to the presence of a rapid population, the prevalence of cancer, and improving the healthcare infrastructure. Because of the growing awareness of epigenetics, the expansion of the R&D sector, and the increase in penetration of significant companies in Asia-Pacific, the epigenetics market in Asia-Pacific provides lucrative possibilities for key players. Also, the presence of major market players such as China, India, and Japan are expanding the APAC regional market growth as these countries are significantly investing in R&D to develop new technologies. In addition, en Research Consortium, located in the U.K, has expanded its studies center in Singapore for chronic illness research, including diabetes and obesity.
The Chinese epigenetics market dominated the APAC Epigenetics market during the forecast period due to technological advancements in the healthcare sector and the growing adoption of epigenetics procures. In addition, a large geriatric population and growing demand for epigenetics are projected to increase market growth in the coming years.
On the other hand, emerging countries such as Japan and India are anticipated to witness a promising share in the APC epigenetics market during the forecast period. Especially the Indian Epigenetics market is likely to expand significantly due to the favorable government incentives, improving healthcare sector, and the growing usage of epigenetics for various applications has led to developments in the market India. Many pharmaceutical firms and research institutions in India spend a significant amount of time establishing modified genes.
KEY MARKET PLAYERS:
Abcam plc., Illumina, Inc., QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc. and Zymo Research Corporation are some of the prominent companies in the APAC epigenetics market.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
220.127.116.11 DNA-Modifying Enzymes
18.104.22.168 Protein-Modifying Enzymes
22.214.171.124 RNA-Modifying Enzymes
5.1.3 Instruments & Consumables
126.96.36.199 Mass Spectrometers
188.8.131.52 Next-Generation Sequencers
184.108.40.206 Bisulfite Conversion KITS
220.127.116.11 Chip-Sequence KITS
18.104.22.168 RNA Sequencing KITS
22.214.171.124 Whole-Genome Amplification KITS
126.96.36.199 5-HMC and 5-MC Analysis KITS
188.8.131.52 Magnetic Beads
5.1.6 Y-o-Y Growth Analysis, By Product
5.1.7 Market Attractiveness Analysis, By Product
5.1.8 Market Share Analysis, By Product
5.2 Research Area
5.2.2 Developmental Biology
5.2.4 Drug Delivery
5.2.5 Y-o-Y Growth Analysis, By Research Area
5.2.6 Market Attractiveness Analysis, By Research Area
5.2.7 Market Share Analysis, By Research Area
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Research Area
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Research Area
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Research Area
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abcam plc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Illumina, Inc.
8.3 QIAGEN N.V.
8.4 Merck & Co.
8.5 New England Biolabs, Inc.
8.6 Zymo Research Corporation
8.7 Sigma-Aldrich Corporation
8.8 Thermo Fisher Scientific, Inc.
8.9 Active Motif
8.10 Diagenode, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.